20.10.2014 • News

Aesica appoints VP, Business Development and Business Development Director for Finished Dose

Aesica announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Behrens has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Wrabletz is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany.

Prior to working for Aesica, Behrens held senior business development roles at Piramal and Next Pharma. As a qualified pharmacist he holds a PhD, and is a Board member and member of the Education Committee of DCAT.

Wrabletz holds a Diplom-Betriebswirt (FH) and a Bachelor of Arts in International Business Administration and joined Aesica from Clondalkin, a packaging specialist.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read